Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05046782 | Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT06527690 | Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer(REPRESENTATION) | withdrawn | Phase 2 | 0 | Latin American Cooperative Oncology GroupOTHER | 0 |
| Sep 29, 2025 |
| clinicaltrials |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Sep 23, 2025 | clinicaltrials |
| NCT02869282 | Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer(CHEMOPROST) | withdrawn | — | 0 | Institut BergoniéOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06058728 | A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)(Pink Orchid) | withdrawn | — | 0 | AbbVieINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04053114 | MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii(MOLTHYSO) | withdrawn | — | 0 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04580667 | Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity | withdrawn | — | 0 | DiaCarta, Inc.INDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT04569461 | Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)(TALON) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04688333 | iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma | withdrawn | — | 0 | City of Hope Medical CenterOTHER | 0 | Jun 26, 2025 | clinicaltrials |
| NCT05333432 | Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer(HRPCa-II) | withdrawn | N/A | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT05687721 | Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | withdrawn | Phase 1 / Phase 2 | 0 | VA Office of Research and DevelopmentFED | 1 | Jun 15, 2025 | clinicaltrials |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 3, 2025 | clinicaltrials |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | withdrawn | Phase 3 | 0 | National Institute of CancerologíaOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) | withdrawn | Phase 1 / Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery | withdrawn | Early Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT06795178 | Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer(KATANA E3M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06795191 | Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer(KATANA E6M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05815316 | 18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer | withdrawn | Phase 2 | 0 | IRCCS San RaffaeleOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | withdrawn | Phase 1 | 0 | Orion Biotechnology Polska Sp. z o.o.INDUSTRY | 0 | Apr 9, 2025 | clinicaltrials |
| NCT05126342 | Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi | withdrawn | Phase 2 | 0 | AGO Research GmbHINDUSTRY | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06422312 | A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients. | withdrawn | N/A | 0 | Guangzhou Red Pine Medical Instrument Co., Ltd.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06385548 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer(LiDer) | withdrawn | Phase 1 / Phase 2 | 0 | Vall d'Hebron Institute of OncologyOTHER | 0 | Apr 1, 2025 | clinicaltrials |
| NCT05192850 | Endometrial Cancer Recurrence in Patients Taking Metformin | withdrawn | — | 0 | WellSpan HealthOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT06457854 | Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone(PROCeed-BR) | withdrawn | — | 0 | AstraZenecaINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04696263 | Single-Port Versus Multi-Port Robotic Radical Prostatectomy | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05470309 | Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women in Cleveland | withdrawn | — | 0 | MetroHealth Medical CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT05714306 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma(CHUV-OVACURE) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Hospitalier Universitaire VaudoisOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03197584 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03632798 | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer(ACSCO) | withdrawn | Phase 3 | 0 | Cordgenics, LLCINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06120972 | Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency | withdrawn | Phase 2 | 0 | Alexander B Olawaiye, MDOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT02608359 | A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer | withdrawn | — | 0 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT02905201 | A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)(TOGETHER) | withdrawn | — | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Feb 3, 2025 | clinicaltrials |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | withdrawn | Phase 1 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT05568537 | Prostate MRI and Pylarify PSMA PET/CT | withdrawn | Phase 4 | 0 | Corewell Health EastOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT05145569 | Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Jan 1, 2025 | clinicaltrials |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | withdrawn | Early Phase 1 | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT01350180 | Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis | withdrawn | — | 0 | Dr. Tamim NiaziOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02588404 | The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient | withdrawn | — | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 10, 2024 | clinicaltrials |
| NCT04064190 | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | withdrawn | Phase 2 | 0 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04530019 | Brachytherapy Innovations in Gynecologic Cancer | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Nov 29, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Sep 30, 2025source: clinicaltrials